The mouse lymphoma assay detects recombination, deletion, and aneuploidy.
The mouse lymphoma assay (MLA) uses the thymidine kinase (Tk) gene of the L5178Y/Tk(+/-)-3.7.2C mouse lymphoma cell line as a reporter gene to evaluate the mutagenicity of chemical and physical agents. The MLA is recommended by both the United States Food and Drug Administration and the United States Environmental Protection Agency as the preferred in vitro mammalian cell mutation assay for genetic toxicology screening because it detects a wide range of genetic alterations, including both point mutations and chromosomal mutations. However, the specific types of chromosomal mutations that can be detected by the MLA need further clarification. For this purpose, three chemicals, including two clastogens and an aneugen (3'-azido-3'-deoxythymidine, mitomycin C, and taxol), were used to induce Tk mutants. Loss of heterozygosity (LOH) analysis was used to select mutants that could be informative as to whether they resulted from deletion, mitotic recombination, or aneuploidy. A combination of additional methods, G-banding analysis, chromosome painting, and a real-time PCR method to detect the copy number (CN) of the Tk gene was then used to provide a detailed analysis. LOH involving at least 25% of chromosome 11, a normal karyotype, and a Tk CN of 2 would indicate that the mutant resulted from recombination, whereas LOH combined with a karyotypically visible deletion of chromosome 11 and a Tk CN of 1 would indicate a deletion. Aneuploidy was confirmed using G-banding combined with chromosome painting analysis for mutants showing LOH at every microsatellite marker on chromosome 11. From this analysis, it is clear that mouse lymphoma Tk mutants can result from recombination, deletion, and aneuploidy.
Wang
Jianyong
J
Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research/ Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA.
Sawyer
Jeffrey R
JR
Chen
Ling
L
Chen
Tao
T
Honma
Masamitsu
M
Mei
Nan
N
Moore
Martha M
MM
D000782:Aneuploidy; D000818:Animals; D000963:Antimetabolites / Q000633:toxicity; D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D033481:Chromosomes, Mammalian / Q000187:drug effects; D020732:Cytogenetic Analysis; D017353:Gene Deletion; D018628:Gene Dosage / Q000187:drug effects; D019656:Loss of Heterozygosity / Q000187:drug effects; D008223:Lymphoma; D008677:Metaphase / Q000187:drug effects; D051379:Mice; D016685:Mitomycin / Q000633:toxicity; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D019384:Nucleic Acid Synthesis Inhibitors / Q000633:toxicity; D017239:Paclitaxel / Q000633:toxicity; D011995:Recombination, Genetic / Q000187:drug effects*; D013937:Thymidine Kinase / Q000235:genetics*; D015215:Zidovudine / Q000633:toxicity
D000963:Antimetabolites; D000972:Antineoplastic Agents, Phytogenic; D009153:Mutagens; D019384:Nucleic Acid Synthesis Inhibitors; D015215:Zidovudine; D016685:Mitomycin; D013937:Thymidine Kinase; D017239:Paclitaxel